Market Minds Advisory
Cryogenic Vials and Tubes Market

Cryogenic Vials and Tubes Market: Cell and Gene Therapy Manufacturing Rewrites Demand for a Legacy Lab Consumable

Cell and gene therapy manufacturing scale-up and expanding biobank sample volume are pulling cryogenic vial and tube demand toward traceable, ultra-low-temperature-validated formats faster than legacy consumable suppliers can requalify their product lines against clinical-grade specifications.

Lead Analyst

Bilal Shaikh

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$1.8BMarket Size 2025
2036 FORECAST VALUE$4.5BBase Case , 2026 to 2036
CAGR 2026 TO 20368.8 %Bull 10.0% / Bear 7.5%
INCREMENTAL OPPORTUNITY$2.6BNet 10- year value creation
EXPANSION MULTIPLE2.32x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Cryogenic vial and tube demand is shifting from a commodity lab consumable purchase into a clinical-grade specification requirement as cell and gene therapy manufacturers and large biobanks demand traceability and validated cold-chain performance that generic vials cannot reliably provide across their full production runs.
2D-barcoded cryogenic tubes are pulling investment fastest as biobanks and cell therapy manufacturers require sample-level traceability across every freeze-thaw cycle a specimen undergoes from collection through eventual clinical use. Cryogenic storage bags follow closely behind, driven by bulk cell therapy cryopreservation needs that individual vials cannot serve efficiently at commercial manufacturing scale. North America commands the largest cell and gene therapy manufacturing base, while East Asia carries the fastest-growing demand tied to China's expanding biopharmaceutical manufacturing investment nationwide.
Five manufacturers hold roughly 42 percent of category revenue, leaving substantial share open to specialists who move fastest on clinical-grade validation and cold-chain qualification testing across programs. A technology transition toward traceable, automation-compatible formats, combined with expanding cell and gene therapy manufacturing capacity, is reshaping which suppliers win the largest biopharmaceutical and biobank contracts over the coming decade of growth.
Market Definition
The market comprises single-use plastic vials, tubes, straws, and bags engineered for storage of biological samples at cryogenic and ultra-low temperatures, including external and internal thread cryovials, 2D-barcoded cryogenic tubes, cryogenic storage bags, cryogenic straws, and associated cryogenic storage boxes and racks. It excludes cryogenic storage tanks, freezers, and liquid nitrogen dewars sold as capital equipment rather than consumable containers.
Base Year Value
$1.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.8% base case. Bull 10.0%. Bear 7.5%.
Fastest Growth Segment
2D-Barcoded Cryogenic Tubes: 12.5% CAGR
Fastest Growth Country
China: 12.2% CAGR
Fastest Growth Region
South Asia and Pacific: 10.9% CAGR
Largest Region
North America: 30% of 2025 global value
Market Leaders
Thermo Fisher Scientific, Corning, Azenta Life Sciences, Greiner Bio-One, Sarstedt. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Cryogenic Vials and Tubes Market Forecast Scenarios

cryogenic-vials-and-tubes-market-size-forecast-scenario-1787300826005
Between 2020 and 2025 the market grew at a historical pace of 7.8 percent as expanding biobank sample collection and early cell and gene therapy manufacturing investment pulled demand toward higher-specification vial formats faster than most legacy consumable suppliers had originally planned production capacity around at this scale industry-wide.
The base case rests on three commercial mechanisms holding together over the decade: continued expansion of global cell and gene therapy manufacturing capacity requiring validated, traceable cryogenic containers across every stage of the production and distribution chain, growing biobank sample volume tied to population health research initiatives across major national governments, and rising demand for automation-compatible 2D-barcoded formats that integrate directly with robotic sample handling systems now standard across large biobanks.
A bull scenario hinges on cell and gene therapy approvals accelerating faster than current regulatory pipelines suggest, pulling forward validated container demand well ahead of schedule. The bear case centers on a slowdown in biopharmaceutical capital spending that would compress the fastest-growing clinical-grade segment faster than biobanking and reproductive medicine volume could offset the resulting revenue gap.

Commodity Consumable Meets Clinical-Grade Specification

Three forces are converging on this category at once: a broad research and reproductive medicine base that still anchors the largest unit volume, a fast-scaling cell and gene therapy manufacturing segment that pays materially higher prices per validated container, and a large biobank sample collection base that increasingly demands automation-compatible, traceable formats over generic vials purchased on price alone.
MARKET CONCENTRATIONCR5 42%top five manufacturers hold roughly two-fifths of total revenue
AVERAGE UNIT PRICE$0.85/unitblended average selling price across all cryogenic container formats
LEADING PRODUCING REGIONNorth America, 30% sharelargest single-region demand base by manufacturing contract volume
CELL THERAPY DEMAND SHARE29% of revenueproportion of category revenue tied to cell and gene therapy manufacturing
FREEZE-THAW CYCLE RATING5 to 10 cyclestypical certified freeze-thaw tolerance before container integrity fails
RESIN INPUT COST SHARE29% of COGSpolypropylene and specialty resin proportion of total goods sold
Commercially, the market increasingly splits along validation tier rather than pure product-class lines. Academic and general research buyers still purchase largely on price and delivery lead time, while cell and gene therapy manufacturers and large biobanks evaluate suppliers on documented cold-chain validation data, extractables and leachables testing, and manufacturing traceability far more heavily than price alone.
Over the next decade, validation depth will matter as much as raw manufacturing scale. Suppliers who move fastest through clinical-grade qualification testing and automation compatibility certification will capture a disproportionate share of the fastest-growing cell therapy and biobank order categories before the broader commodity-grade supplier base can match those specifications.
"Nobody used to care much who made the little plastic tube. Now a cell therapy manufacturer will reject an entire lot over a container's extractables profile, and that is a different supplier relationship entirely."
Director, Biobanking and Cell Therapy Consumables Practice · MMA Biobanking and

Market Trends

Cell Therapy Manufacturers Demand Validated Traceable Containers

Cell and gene therapy manufacturers increasingly require cryogenic containers with documented chain-of-custody traceability and validated extractables and leachables testing, reflecting the regulatory scrutiny applied to any material contacting a patient-specific cellular product during manufacturing. This requirement has pushed container qualification testing cycles to twelve months or longer per new manufacturing program, a bottleneck favoring suppliers with dedicated regulatory affairs and validation testing capability over general lab consumable manufacturers lacking comparable clinical-grade experience. Suppliers report that once a container is validated into a manufacturer's approved materials list, switching requires costly requalification most manufacturers strongly prefer to avoid.
Market Impact: Adds demand at 100% of approvals

Biobanks Standardize On Automation-Compatible Formats

Large national and institutional biobanks are increasingly standardizing sample storage around 2D-barcoded tube formats compatible with robotic handling systems, replacing older manually labeled vial formats that cannot support the sample throughput modern biobanking programs require at scale. This standardization is concentrating biobank purchasing around a smaller number of suppliers whose tube dimensions and barcode placement are qualified against major robotic handling equipment platforms already installed across large research institutions. Suppliers with proven automation compatibility are winning multi-year standing order contracts rather than competing for one-off purchase orders, a meaningfully more durable revenue relationship than the category's historical transactional pattern.
Market Impact: 60% of biobanks expand targets yearly

Market Opportunities and Growth Drivers

Cell and Gene Therapy Approvals Expand Manufacturing Demand

The growing number of approved cell and gene therapies across major regulatory markets is directly expanding commercial-scale manufacturing capacity, and each new approved therapy requires validated cryogenic containers across cell collection, processing, storage, and final product distribution stages of its supply chain. Manufacturing capacity expansion announcements across major biopharmaceutical companies have continued at a steady pace in recent years, each representing incremental validated container demand that did not previously exist. This approval-driven demand has proven more durable than pure research-stage consumption, since commercial manufacturing volume scales with patient treatment numbers rather than discretionary research budget cycles that can fluctuate considerably.
Market Impact: Costs exceed $100K per format tested

Population Biobanking Initiatives Sustain Sample Volume Growth

Several national governments have launched or expanded large-scale population health biobanking initiatives intended to support genomic and precision medicine research, each requiring millions of validated cryogenic containers for long-term sample storage across decades of intended research use. Roughly 60 percent of major biobanking programs tracked in recent industry surveys report expanding annual sample collection targets rather than holding volume steady, reflecting sustained institutional commitment to these long-horizon research initiatives. This government-backed demand base provides a more stable growth floor than purely commercial research spending, since these programs typically operate on multi-decade funding commitments rather than short-term budget cycles.
Market Impact: Swings resin costs over 20% yearly

Market Restraints and Challenges

Extractables and Leachables Testing Raises Entry Barriers

Cell and gene therapy manufacturers require extensive extractables and leachables testing data before qualifying a new cryogenic container supplier, a process that can cost well into six figures per format and commonly takes over a year to complete given the rigor required. The root cause is the genuinely high patient safety stakes of any chemical migration from packaging into a cellular therapy product during storage. The commercial impact concentrates cell therapy revenue among a small number of already-validated suppliers even as the broader research-grade market remains comparatively open. Smaller manufacturers mitigate this by partnering with validated incumbents on private-label arrangements.
Market Impact: Ties 29% of revenue

Resin Price Volatility Squeezes Manufacturing Margins

Polypropylene and specialty cryogenic-grade resin prices have swung noticeably over the past several years amid petrochemical feedstock volatility, a cost pressure affecting cryogenic container manufacturers similarly to the broader plastic consumables industry generally. The root cause is the category's continued reliance on petrochemical-derived resins engineered to withstand extreme temperature cycling without embrittlement, a specialty formulation with a more concentrated supplier base than standard commodity plastics. The commercial impact shows up in periodic price surcharges passed to customers mid-contract, particularly affecting suppliers without long-term resin agreements. Manufacturers mitigate exposure through multi-year agreements and formulation diversification.
Market Impact: Locks in 3 to 5 year orders
3 additional market trends, 3 additional growth drivers, and 4 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows container format, the dimension biobanks, cell therapy manufacturers, and researchers use to select cryogenic storage for a given sample type and handling requirement across this market. Cryogenic storage bags are treated as a distinct category given their bulk-volume manufacturing function relative to individual sample vial formats sold separately at retail.
cryogenic-vials-and-tubes-market-market-share-analysis-1787300826534

2D-Barcoded Cryogenic Tubes

2D-barcoded cryogenic tubes are the fastest-growing product category, featuring a laser-etched barcode on the tube base that enables automated identification and tracking through robotic sample handling systems without requiring manual label reading at any point. This format has become the standard for large biobanks and cell therapy manufacturers who must maintain sample-level traceability across potentially decades of storage involving different personnel and facilities over that time. Demand concentrates among institutions that have already invested in robotic sample handling infrastructure, since the barcode format must be qualified against specific equipment platforms before large-scale adoption becomes practical. Suppliers with proven compatibility across multiple major robotic handling platforms are winning a disproportionate share of new institutional contracts, since requalifying tube dimensions against automated equipment is costly enough that most biobanks strongly prefer to standardize around a single supplier.
CAGR 12.5%

Cryogenic Storage Bags

Cryogenic storage bags, used for bulk cryopreservation of cell therapy products and other biological materials at volumes individual vials cannot efficiently accommodate, form the second-fastest-growing category as commercial-scale cell therapy manufacturing expands beyond early clinical-stage production volumes. These bags require validated closed-system compatibility with cell processing equipment, a more demanding qualification standard than most vial applications given the direct manufacturing integration required. Demand concentrates almost entirely among cell and gene therapy manufacturers rather than general biobanking or research users, who typically have no bulk-volume storage need at all. Suppliers with proven closed-system manufacturing compatibility and validated cold-chain performance hold a meaningful advantage over vial-focused competitors extending into this more technically demanding bulk-format segment without comparable integration experience.
CAGR 11.0%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America commands the largest cell and gene therapy manufacturing base and biobanking infrastructure, East Asia follows closely on China's expanding biopharmaceutical investment, and South Asia and Pacific is the fastest-growing region on expanding domestic research infrastructure.

North America

The United States carries the region's largest cell and gene therapy manufacturing base, anchored by the majority of currently approved therapies produced domestically and a substantial pipeline of additional candidates advancing through clinical trials toward eventual commercial manufacturing scale. Major national biobanking initiatives, including large government-funded population health research programs, sustain a parallel demand pool distinct from commercial cell therapy manufacturing entirely. Canada's growing life sciences sector, supported by federal research investment, is expanding its own cell therapy manufacturing footprint at a smaller scale than its southern neighbor. Mexico's contract research and reproductive medicine sectors sustain steady demand for standard cryogenic vial formats tied to established fertility clinic networks across the country.
Share: 30% | CAGR: 8.2% (2026 to 2036)

Western Europe

Germany and the United Kingdom both host substantial cell and gene therapy manufacturing capacity, supported by strong academic research infrastructure and government funding programs that have prioritized advanced therapy manufacturing as a strategic national industrial priority in recent years. Several major European biobanking initiatives, including national genomic research programs, sustain steady institutional demand for automation-compatible tube formats across the region's leading research universities. France's reproductive medicine sector, among the most established in the region, maintains strong demand for cryogenic straws and vials tied to fertility treatment volume. The Netherlands and Switzerland both host significant biopharmaceutical manufacturing operations sustaining premium validated container demand tied to their concentrated life sciences industry clusters.
Share: 22% | CAGR: 7.3% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
cryogenic-vials-and-tubes-market-country-cagr-analysis-1787300827083

Where Suppliers Can Defend Category Margin

As commodity research-grade vial pricing compresses, suppliers are shifting commercial strategy toward clinical-grade validation investment, automation compatibility certification, and long-term biobank supply agreements to defend margin across the category's fastest-growing segments over the coming decade.

Complete Clinical-Grade Validation Testing Ahead of Demand

Suppliers who complete extractables and leachables testing and secure cell therapy manufacturer qualification ahead of competitors are winning a disproportionate share of new manufacturing program contracts, since manufacturers strongly prefer already-validated containers over unproven formats given the patient safety stakes involved in cellular therapy production. Suppliers with completed validation report qualification win rates roughly 3x higher than competitors still building their testing data package from scratch. This lever requires meaningful upfront investment in regulatory and testing infrastructure but converts into a durable, multi-year revenue relationship considerably more predictable than commodity research-grade sales alone.
Market Impact: Triples qualification win rate to 3x

Certify Broad Robotic Handling Platform Compatibility

Suppliers who certify their 2D-barcoded tube formats against multiple major robotic sample handling platforms, rather than a single equipment vendor, can serve biobanks regardless of which automation system a given institution has already installed across its research facilities. Suppliers with broad platform compatibility report winning large biobank standing order contracts at rates roughly 2x higher than competitors certified against only one automation platform available today. This lever requires sustained engineering investment but positions suppliers to capture share as biobanks increasingly consolidate purchasing under fewer, broadly compatible vendors.
Market Impact: Wins contracts at a 2x higher rate

Build Long-Term Biobank Standing Order Agreements

Suppliers who secure multi-year standing order agreements with large national and institutional biobanks convert a historically transactional purchase-order business into a predictable recurring revenue relationship that guarantees volume well beyond what one-off competitive bidding ever reliably delivered for the category historically across most institutional accounts. Suppliers with standing order agreements report customer retention rates roughly 40 percent higher than competitors relying on repeated competitive rebidding for every purchase cycle. This lever requires sustained institutional relationship investment but delivers outsized revenue predictability once a standing agreement is successfully established.
Market Impact: Lifts customer retention roughly 40%

Expand Closed-System Manufacturing Integration Capability

Suppliers who develop cryogenic bag and container formats with validated closed-system compatibility for cell therapy manufacturing equipment are capturing premium pricing from manufacturers who value the reduced contamination risk and regulatory simplicity of an integrated, validated system over assembling components from multiple unvalidated suppliers separately. Suppliers offering closed-system integration report contract values roughly 30 percent above comparable standalone component sales for similar manufacturing volume across accounts. This lever rewards suppliers with deep manufacturing engineering capability over pure consumable specialists lacking that integration expertise.
Market Impact: Commands roughly a 30 percent premium

Who Controls the Margin Pool

The top five manufacturers hold roughly 42 percent of revenue on a company-revenue basis, a moderately concentrated structure reflecting how commodity research-grade vials remain accessible to regional specialists even as clinical-grade cell therapy formats concentrate among a narrower set of validated suppliers. The gap between Thermo Fisher Scientific and Azenta Life Sciences, two of the largest players, and the broader field remains meaningful but leaves substantial room for specialists.
Current competitive activity centers on three fronts: clinical-grade validation races to secure cell therapy manufacturer qualification ahead of competitors, robotic handling platform compatibility certification designed to win large biobank standing order contracts, and closed-system manufacturing integration investment intended to capture premium cell therapy bag and container pricing.

Pressure is building from specialty life sciences consumable manufacturers, particularly those with existing biobanking relationships, who are moving up the value chain from standard vial supply into premium clinical-grade formats that historically only the largest diversified suppliers could reliably provide. Several have already won reference qualifications at major cell therapy manufacturers, evidence that could accelerate their move into higher-margin segments faster than incumbents currently expect.
cryogenic-vials-and-tubes-market-company-positioning-matrix-1787300827603

Competitive Moat and Risk Dimensions

THERMO FISHER SCIENTIFIC INC.

Moat: Broadest Life Sciences Manufacturing Scale

Thermo Fisher Scientific operates one of the largest life sciences consumables manufacturing footprints globally, giving it existing biopharmaceutical customer relationships and production scale that narrower cryogenic-only specialists cannot easily match across as many product categories and geographies at once simultaneously.
THERMO FISHER SCIENTIFIC INC.

Risk: Small Portfolio Niche

Cryogenic vials and tubes represent a comparatively small piece of Thermo Fisher Scientific's overall diversified life sciences portfolio, meaning the category may receive less dedicated management attention and capital priority than it would within a more singularly focused specialist competitor entirely.
AZENTA LIFE SCIENCES, INC.

Moat: Deepest Biobanking Sample Management Expertise

Azenta Life Sciences built its business specifically around biobanking and sample management, giving it deeper institutional relationships and automation compatibility expertise than diversified competitors who treat cryogenic consumables as one product line among many unrelated categories entirely across their portfolios.
AZENTA LIFE SCIENCES, INC.

Risk: Narrow Diversified Revenue Base

Azenta Life Sciences' concentrated focus on biobanking and sample management leaves it with less revenue diversification than broad life sciences conglomerates, potentially limiting its ability to fund aggressive capacity expansion during a sustained industry-wide demand downturn across markets.

Key Players

Thermo Fisher Scientific Inc.
Corning Incorporated
Azenta Life Sciences, Inc.
Greiner Bio-One International GmbH
Sarstedt AG & Co. KG

Others

Avantor, Inc.
Merck KGaA (MilliporeSigma)
Eppendorf SE
Simport Scientific Inc.
Cryo Bio System (IMV Technologies)
Micronic B.V.
Porvair Sciences Ltd.
Argos Technologies Inc.
Cook Regentec
STARLAB International GmbH
Bio-Rad Laboratories Inc.
PHC Holdings Corporation
Labcon North America
Neta Scientific Inc.
DWK Life Sciences

Recent Developments

MARCH 2025

Thermo Fisher Scientific Expands Cryovial Manufacturing Capacity

Thermo Fisher Scientific announced an organic capacity expansion at an existing North American facility dedicated to clinical-grade cryovial production, adding manufacturing capacity to meet growing cell therapy manufacturer demand without relying on capacity from its other global manufacturing sites elsewhere.
Signal: Established diversified suppliers are increasingly committing dedicated capacity to meet rising clinical-grade cryovial demand.
AUGUST 2025

Azenta Life Sciences Signs Multi-Year Supply Agreement With Cell Therapy Manufacturer

Azenta Life Sciences signed a multi-year supply agreement, not an acquisition or joint venture, with a major cell therapy manufacturer to provide validated cryogenic storage bags and tubes across the manufacturer's commercial production network, securing predictable long-term order volume through 2030.
Signal: Cell therapy manufacturers are increasingly securing long-term validated container supply ahead of production scale-up plans.
JANUARY 2026

Greiner Bio-One Acquires Specialty Cryogenic Bag Manufacturer

Greiner Bio-One completed the acquisition of a specialty cryogenic storage bag manufacturer, adding closed-system manufacturing integration capability rather than continuing to develop comparable bulk-format technology organically from an earlier internal starting point within the company.
Signal: Established vial manufacturers are increasingly acquiring bulk-format capability to serve expanding cell therapy manufacturing demand.

Specialty Cryogenic-Grade Resin Exposure

Polypropylene and specialty cryogenic-grade resin formulations together account for roughly 29 percent of cost of goods sold across the category, with molding, sterilization, and quality validation labor making up most of the remainder of total manufacturing cost. Cryogenic-grade resin capable of withstanding extreme temperature cycling without embrittlement concentrates among a relatively small number of specialty polymer producers serving this and adjacent industries.
Polypropylene resin prices spiked meaningfully during 2022 amid petrochemical feedstock supply disruptions tied to regional energy market volatility, a period several manufacturers described in earnings materials as among the more volatile stretches for polymer input pricing in recent years across the broader plastics sector. Several smaller cryogenic container manufacturers disclosed margin compression during this period directly attributable to this broader resin price volatility affecting the entire industry.

Exposure varies by company scale and integration. Larger diversified manufacturers with long-term resin supply agreements or partial backward integration into resin formulation absorbed the volatility with comparatively limited disruption, while smaller specialists reliant entirely on spot-market resin purchasing faced sharper cost swings that occasionally opened share for better-hedged competitors during the tightest supply quarters of the cycle.
cryogenic-vials-and-tubes-market-cost-volatility-analysis-1787300827800

Lock In Multi-Year Cryogenic Resin Supply Agreements

Leading manufacturers are increasingly securing multi-year fixed-volume agreements directly with specialty resin producers, trading some pricing flexibility for meaningfully greater supply certainty during periods of tight global petrochemical capacity affecting the broader plastics industry across most producing regions worldwide.

Qualify Alternative Cryogenic-Grade Resin Formulations

Manufacturers are qualifying alternative cryogenic-grade resin formulations from a more diversified supplier base, reducing dependence on the narrowest, most supply-constrained specialty polymer sources without compromising the extreme temperature performance customers require in continuous cold storage.

Invest In Backward Integration Into Resin Compounding

Several of the largest suppliers have built or acquired captive resin compounding capacity, insulating a meaningful share of production from third-party pricing pressure and allowing faster new product development cycles than competitors relying entirely on external resin suppliers.

Portfolio Architecture for Margin Defence

The market splits into three commercial tiers with distinct margin economics. Commodity research-grade vials compete largely on price and delivery lead time, validated automation-compatible tube formats carry meaningfully higher margin on biobank standing order relationships, and clinical-grade cell therapy containers command the highest margin given their narrow qualified supplier base and manufacturer lock-in.
The tension between volume and premium positioning shapes how manufacturers allocate validation investment: commodity research-grade vials still represent the largest unit volume by a wide margin across academic and general research channels, but nearly all incremental profit growth over the forecast period concentrates in clinical-grade and automation-compatible formats, where the leading suppliers increasingly direct testing and certification spending.

High-value margin pools concentrate specifically in clinical-grade cell therapy containers during their current validation-advantage window and in automation-compatible tubes serving large biobank standing order relationships. Both pools reward manufacturers who invest ahead of demand in validation and compatibility testing rather than those who wait for institutional programs to mature before committing capital.

Volume / Commodity-Adjacent Tier

Commodity research-grade vials and straws sold largely on price and delivery lead time across broad academic and general research channels worldwide serving most institutions.
Gross Margin: 16-26%

Premium / Certified Tier

Automation-compatible 2D-barcoded tube formats with proven robotic handling certification, commanding meaningful premiums tied directly to biobank standing order relationships already established.
Gross Margin: 30-40%

Sustainability / Regulatory / Next-Generation Tier

Clinical-grade cell therapy containers with completed extractables and leachables validation, carrying the category's highest margins given the narrow qualified supplier base worldwide.
Gross Margin: 42-55%
cryogenic-vials-and-tubes-market-portfolio-architecture-1787300828291

High-value Sub-segments and Strategic Watch-out

2D-Barcoded Cryogenic Tubes

Highest current growth in the category, driven by biobank automation standardization, though constrained by the small number of suppliers with broad robotic handling platform compatibility today across systems.
Gross Margin: 32-42%

Cryogenic Storage Bags

Steady high-value growth tracking cell therapy manufacturing capacity expansion closely, increasingly favoring suppliers with validated closed-system integration over standalone vial specialists lacking it.
Gross Margin: 42-54%

Commodity Research-Grade Vials

The volume core of the market by unit count, competing primarily on price and delivery lead time rather than deep technical differentiation between competing regional suppliers across channels.
Gross Margin: 16-24%

Unvalidated Generic Cryovial Formats

A strategic watch-out segment as cell therapy manufacturers increasingly require documented validation data that generic, unvalidated formats cannot provide without substantial additional testing investment upfront.
Gross Margin: 10-20%

Consumable Purchase Meets Manufacturing Lock-In

Commodity research-grade cryogenic vials have historically behaved as a transactional, price-sensitive purchase with minimal switching costs, but the clinical-grade and biobank segments are shifting toward a far stickier model as manufacturers and institutions require lengthy validation processes that create durable, multi-year purchasing relationships once a container is locked into an approved materials list or automation platform.
Adoption depth varies sharply by end-use vertical. Cell and gene therapy manufacturers show the deepest supply relationship lock-in given the cost and regulatory complexity of requalifying a new container mid-production, large institutional biobanks adopt standing order relationships once automation compatibility is proven, and academic and general research buyers remain the most transactional and price-driven segment of the entire market.

A generational shift in buyer profile is underway as cell therapy manufacturing procurement teams increasingly include dedicated quality and validation specialists rather than pure purchasing generalists trained under an older cost-focused sourcing model. Biobank procurement teams are also increasingly staffed by informatics specialists who evaluate automation compatibility data rather than simply comparing per-unit vial pricing between competing suppliers.
cryogenic-vials-and-tubes-market-end-use-penetration-index-1787300828779

Where This Market Goes Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CLINICAL VALIDATION INVESTMENT

Early-validated suppliers will lock in a durable manufacturing lead

Cell and gene therapy manufacturers rarely switch container suppliers once a format is validated into their approved materials list, given the cost and regulatory risk of requalification mid-production. Suppliers who completed extractables and leachables testing early are already winning a disproportionate share of new manufacturing program contracts across the industry. This gap should widen rather than narrow as validated suppliers accumulate manufacturing relationships that unvalidated competitors cannot replicate quickly regardless of how much capital they eventually commit to catching up on testing.
02 / AUTOMATION COMPATIBILITY SCALE

Broad robotic platform certification is winning the largest biobanks

Large biobanks increasingly prefer consolidating purchasing under suppliers whose tube formats are certified across multiple robotic handling platforms, rather than managing separate vendor relationships for each automation system installed across their many facilities and clinical departments nationwide. Suppliers with broad compatibility certification are winning larger, more durable standing order contracts than narrowly certified competitors bidding the same institutional accounts today. This consolidation trend should continue as more biobanks invest in automation infrastructure, widening the gap between broadly certified suppliers and narrow single-platform competitors over the coming years.
03 / CLOSED-SYSTEM INTEGRATION STRATEGY

Manufacturing-integrated formats are capturing the category's premium

Cell therapy manufacturers increasingly value validated closed-system container formats that reduce contamination risk and regulatory complexity relative to assembling unvalidated components from multiple suppliers separately across a production line. Suppliers offering closed-system integration are commanding meaningfully higher contract values than standalone component sellers competing on the same manufacturing accounts today. Manufacturers who continue selling only standalone components without integration capability risk losing share to competitors who understand cell therapy manufacturing as a systems engineering problem rather than a simple consumable purchase.
04 / STANDING ORDER STRATEGY

Multi-year institutional agreements are reshaping category economics

Large national and institutional biobanks increasingly prefer multi-year standing order agreements over repeated competitive rebidding, rewarding suppliers who invest early in the institutional relationships and automation certification these agreements require before formal procurement processes even begin at all. Suppliers with established standing order relationships report meaningfully higher customer retention than competitors relying on transactional purchase orders alone. This lever requires patient, multi-year investment but delivers outsized revenue predictability once an institutional relationship is successfully established and proven.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Cryogenic Vials and Tubes Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Cryogenic Vials and Tubes Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a regional cell therapy manufacturer preparing to scale commercial production following recent regulatory approval, expecting to treat several thousand patients annually (client-reported, unverified by MMA) once production reaches full capacity. The company had relied on a single unvalidated container supplier throughout clinical development and needed a qualified commercial supply strategy before scaling manufacturing volume.
STRATEGIC CHALLENGE
Leadership needed to qualify commercial-scale cryogenic container suppliers capable of meeting the manufacturer's aggressive production ramp timeline, while avoiding the regulatory risk of switching to an unproven supplier mid-scale-up during a commercially critical launch period with significant revenue exposure.
MMA APPROACH
MMA benchmarked candidate suppliers against extractables and leachables validation status, manufacturing capacity, and closed-system compatibility, modeled expected qualification timelines under three distinct sourcing scenarios, and recommended a dual-sourcing approach balancing supply security against the manufacturer's compressed commercial launch timeline across its full network.
KEY FINDINGS
  1. Only two of seven candidate suppliers evaluated maintained completed extractables and leachables validation data sufficient to meet the manufacturer's regulatory submission timeline requirements.
  2. Dual-sourcing across two qualified suppliers was modeled to reduce single-supplier disruption risk by roughly 45 percent relative to a single-source commercial supply strategy.
  3. Closed-system bag compatibility varied meaningfully across candidate suppliers, with only one offering full validated integration with the manufacturer's existing processing equipment platform.
  4. Total qualification timeline varied by more than four months across candidate suppliers, materially affecting which suppliers could realistically support the planned commercial launch date.
CLIENT PROFILE
The client is a regional cell therapy manufacturer preparing to scale commercial production following recent regulatory approval, expecting to treat several thousand patients annually (client-reported, unverified by MMA) once production reaches full capacity. The company had relied on a single unvalidated container supplier throughout clinical development and needed a qualified commercial supply strategy before scaling manufacturing volume.
STRATEGIC CHALLENGE
Leadership needed to qualify commercial-scale cryogenic container suppliers capable of meeting the manufacturer's aggressive production ramp timeline, while avoiding the regulatory risk of switching to an unproven supplier mid-scale-up during a commercially critical launch period with significant revenue exposure.
MMA APPROACH
MMA benchmarked candidate suppliers against extractables and leachables validation status, manufacturing capacity, and closed-system compatibility, modeled expected qualification timelines under three distinct sourcing scenarios, and recommended a dual-sourcing approach balancing supply security against the manufacturer's compressed commercial launch timeline across its full network.
KEY FINDINGS
  1. Only two of seven candidate suppliers evaluated maintained completed extractables and leachables validation data sufficient to meet the manufacturer's regulatory submission timeline requirements.
  2. Dual-sourcing across two qualified suppliers was modeled to reduce single-supplier disruption risk by roughly 45 percent relative to a single-source commercial supply strategy.
  3. Closed-system bag compatibility varied meaningfully across candidate suppliers, with only one offering full validated integration with the manufacturer's existing processing equipment platform.
  4. Total qualification timeline varied by more than four months across candidate suppliers, materially affecting which suppliers could realistically support the planned commercial launch date.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1-3): Complete supplier evaluation and finalize a dual-sourcing agreement across two qualified suppliers identified overall. Phase 2: Phase 2 (Months 4-8): Complete final validation testing and secure committed production capacity across both supplier relationships formed. Phase 3: Phase 3 (Months 9-12): Execute commercial launch supply and establish ongoing quality monitoring across both suppliers continuously.
OUTCOME
Ten months into the engagement, the manufacturer reported successful commercial launch supply across both qualified suppliers with zero container-related quality holds during the initial production ramp (client-reported, unverified by MMA), validating MMA's dual-sourcing recommendation fully.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Cryogenic Vials and Tubes Market?

The market is valued at approximately 1.8 billion dollars in 2025, expanding to roughly 1.96 billion dollars in 2026 as cell and gene therapy manufacturing and biobanking sample volume continue driving demand.

How large will the Cryogenic Vials and Tubes Market be by 2036?

MMA forecasts the market reaching approximately 4.55 billion dollars by 2036, roughly 2.32 times its 2026 value, driven primarily by expanding cell and gene therapy manufacturing capacity worldwide.

What is the CAGR for the Cryogenic Vials and Tubes Market 2026 to 2036?

The base-case compound annual growth rate is 8.8 percent, with a bull scenario of 10.0 percent and a bear scenario of 7.5 percent depending on cell therapy approval pace and biopharma capital spending.

Which segment is growing fastest?

2D-barcoded cryogenic tubes are growing fastest at a 12.5 percent CAGR, roughly 1.42 times the overall market rate, driven by biobank standardization around automation-compatible traceable formats.

Who are the major companies in the Cryogenic Vials and Tubes Market?

Thermo Fisher Scientific, Corning, Azenta Life Sciences, Greiner Bio-One, and Sarstedt lead the market, together holding roughly 42 percent of revenue on a company-revenue basis.

Which country is growing fastest?

China is the fastest-growing country at a 12.2 percent CAGR, driven by expanding domestic biopharmaceutical manufacturing investment and growing cell and gene therapy programs nationwide.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Container Format

  • External Thread Cryovials
  • Internal Thread Cryovials
  • 2D-Barcoded Cryogenic Tubes
  • Cryogenic Storage Straws
  • Cryogenic Storage Bags
  • Cryogenic Storage Boxes and Racks

By End-Use Industry

  • Cell and Gene Therapy Manufacturing
  • Biobanking and Population Research
  • Reproductive Medicine and IVF
  • Academic and Contract Research
  • Pharmaceutical Cold Chain

By Commercial Dimension

  • Direct Manufacturer Supply Contracts
  • Institutional Standing Order Agreements
  • Distributor and Wholesale Channel
  • Academic and Research Retail Channel

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The market covers single-use plastic vials, tubes, straws, and bags engineered for storage of biological samples at cryogenic and ultra-low temperatures, including external and internal thread cryovials, 2D-barcoded cryogenic tubes, cryogenic storage bags, cryogenic straws, and associated cryogenic storage boxes and racks. Cryogenic storage tanks, freezers, and liquid nitrogen dewars sold as capital equipment are excluded.
Quantitative Units
USD billions (current prices); unit shipments where cited
Segmentation Dimensions
By Container Format; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Thermo Fisher Scientific Inc., Corning Incorporated, Azenta Life Sciences, Inc., Greiner Bio-One International GmbH, Sarstedt AG & Co. KG, Avantor, Inc., Merck KGaA (MilliporeSigma), Eppendorf SE, Simport Scientific Inc., Cryo Bio System (IMV Technologies), Micronic B.V., Porvair Sciences Ltd., Argos Technologies Inc., Cook Regentec, STARLAB International GmbH, Bio-Rad Laboratories Inc., PHC Holdings Corporation, Labcon North America, Neta Scientific Inc., DWK Life Sciences
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-214
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Cryogenic Vials and Tubes Market Report (2026 to 2036).

The full report delivers a complete quantitative and strategic assessment of the cryogenic vials and tubes market across all seven regions and more than thirty countries covered in this study. It includes detailed segment-level forecasts through 2036, competitive benchmarking across twenty profiled manufacturers, and primary research drawn from 3,800 survey respondents and 47 expert interviews conducted in Q4 2025. Buyers receive editable data tables and full regional narrative detail beyond the two regions previewed in this summary document. A dedicated appendix covers cell therapy container qualification timelines and biobank automation standards by country.
Fully editable Excel data tables included
All seven full regional narratives included
Twenty-company competitive profiles included
Cell therapy qualification timelines appendix provided
Segment-level 2026-2036 detailed forecasts
Primary survey and interview data provided

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts